海隆控股(01623.HK)簽訂總代價約1.45億元原油管道合同
格隆匯9月21日丨海隆控股(01623.HK)公吿,公司的全資附屬公司海隆管道工程技術服務有限公司("海隆管道")近日與番禺珠江鋼管(連雲港)有限公司("番禺珠江鋼管(連雲港)")簽訂合同,內容有關位於浙江自由貿易區附近的黃澤山-魚山原油管道項目,總代價約人民幣1.45億元。
番禺珠江鋼管(連雲港)為珠江石油天然氣鋼管控股有限公司(股份代號:1938)的全資附屬公司,主要業務為製造及銷售有縫焊接鋼管。黃澤山-魚山原油管道項目是建立石油產品全行業鏈及提高浙江自由貿易區石油行業鏈資源分配能力的重要一步。董事會相信,該合同足證海隆管道的管道塗層服務已獲同行廣泛認可,有助推動集團實現海洋管道建設的戰略過程。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.